Can a low-dose immune drug help hearts heal after a heart attack?
NCT ID NCT07610538
First seen May 29, 2026
Summary
This study gives low-dose interleukin-2 to people who have had a heart attack and are scheduled for bypass surgery. Researchers want to see how the drug affects certain immune cells (regulatory T cells) inside heart tissue compared to blood. The goal is to understand whether these cells can be boosted to help healing, but this is a small early study focused on measuring changes, not on treatment outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital
RECRUITINGCambridge, Cambridgeshire, CB2 0QQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Papworth Hospital NHS Foundation Trust
RECRUITINGCambridge, Cambridgeshire, CB2 0AY, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Interleukin-2 (Aldesleukin)
What this could lead to
If successful, this could point toward a way to improve heart healing after a heart attack by boosting protective immune cells.
What could go wrong
This is a very small, early-phase study with only 24 participants. It is designed to measure immune cell changes, not to test whether the drug improves heart function or outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.